Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
US10537541B2 · kind B2 · utility
0Cited by
38References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 3, 2016 |
| Grant date | Jan 21, 2020 |
| Priority date | — |
| Expiry date | Oct 3, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(E)-octadec-9-enoic acid to treat such diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.